Drugs / LY3971297
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07547540 | Aug 2026 → Nov 2027 expected | diastolic heart failure, systolic heart failure | Eli Lilly and Company | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06148272 | Dec 2023 → Aug 2026 overdue | hypertensive disorder, obesity disorder | Eli Lilly and Company | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LY3971297 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07547540 ↗ |
| Route | Subcutaneous | “administered subcutaneously (SC)” NCT06148272 ↗ |